1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Zhejiang Haisen Pharmaceutical Co., Ltd. Class A

Zhejiang Haisen Pharmaceutical Co., Ltd. Class A

SSZSE:001367
19.66
CNY
+0.64
(+3.36%)
0.72EPS
19.48P/E
2.81BMarket Cap
Zhejiang Haisen Pharmaceutical Co., Ltd. Class A
SZSE:001367
(Shenzhen Stock Exchange)

Recent

price

19.66

P/E

ratio

19.48

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.33
2.38
2.55
3.48
3.79
2.9
3.15
3.56
3.63
Revenue per Share
0.55
0.62
0.56
0.84
0.96
0.76
0.82
0.91
0.95
Basic EPS, GAAP
0.58
0.26
0.5
0.66
0.49
0.17
0.69
0.17
- -
Free Cash Flow per Basic Share
- -
0.1
0.48
0.15
0.01
- -
0.23
0.12
- -
Dividend per Share
1.94
2.38
2.5
3.23
4.2
8.39
8.85
9.8
10.16
Book Value per Share
1.77
2.22
2.33
3.05
4.02
8.25
8.71
9.03
9.39
Tangible Book Value per Share
106
112
112
112
112
137
149
149
151
Basic Weighted Avg Shares
247
267
285
389
423
397
472
532
548
Sales/Revenue/Turnover
26.55
28.41
25.9
28.32
27.4
27.38
26.42
27.91
28.88
Operating Margin (%)
8
9
11
13
14
13
17
24
- -
Depreciation Expense
59
69
63
94
108
105
123
136
143
Net Income, GAAP
13.23
13.92
14.61
13.38
13.08
13.27
13.56
13.32
12.62
Effective Tax Rate (%)
23.74
25.84
22.06
24.17
25.45
26.33
25.99
25.53
26.1
Profit Margin (%)
140
184
190
258
363
1,099
1,136
1,165
1,203
Working Capital
- -
- -
2
1
- -
- -
7
6
6
LT Debt
217
266
279
361
469
1,249
1,344
1,494
1,548
Total Equity
- -
27.9
22.67
28.53
24.64
12.14
9.39
9.47
9.66
Return on Invested Capital (%)
- -
28.38
22.95
29.33
25.87
12.18
9.45
9.54
9.73
Return on Capital (%)
- -
28.54
23.04
29.36
25.91
12.18
9.45
9.58
9.77
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
152
152
152
Market Capitalization
3,344
3,877
2,808

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,281
1,282
1,300
Cash, Cash Equivalents & STI
1,061
1,070
1,088
Accounts Receivable, Net
86
61
74
Inventories
108
108
107
Total Current Liabilities
116
87
97
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
48.88%
11.13%
Free Cash Flow
- -
43.2%
-75.4%
Net Income, GAAP
- -
17.86%
10.87%
Sales/Revenue/Turnover
- -
14.16%
12.88%
Total Cash Common Dividend
- -
- -
-48.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116
95
109
151
472
2025
118
124
- -
173
532
2026
107
144
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.17
0.19
0.24
0.82
2025
0.21
0.2
- -
0.32
0.91
2026
0.19
0.24
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.23
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
Dow Inc. (NYSE:DOW)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
Business
Zhejiang Haisen Pharmaceutical Co., Ltd. is a China-based pharmaceutical manufacturing company primarily engaged in the research, development, production, and commercialization of active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and finished pharmaceutical preparations. Founded in 1998 and headquartered in Dongyang, Zhejiang Province, China, the company operates across the specialty chemicals, human health, and generic pharmaceutical sectors. The company's product portfolio comprises: antipyretic, analgesic, and non-steroidal anti-inflammatory APIs and intermediates, including metamizole sodium (analgin), paracetamol (acetaminophen), dexketoprofen trometamol, and L-lysine acetylsalicylate; cardiovascular system APIs and intermediates, featuring diltiazem hydrochloride and benazepril hydrochloride; digestive system and mucosal protective agents, including sucralfate and glutamine; central nervous system and autonomic agents, such as neostigmine methylsulfate; and finished chemical dosage forms, encompassing diltiazem hydrochloride tablets, metamizole sodium tablets, and sucralfate suspensions. Zhejiang Haisen Pharmaceutical serves pharmaceutical formulation manufacturers, clinical healthcare providers, and chemical distributors across domestic Chinese markets as well as international destinations across Europe, North America, South America, and Asia, holding regulatory accreditations including China NMPA, European EDQM CEP, and U.S. FDA compliance. In recent developments, the company completed its initial public offering and listed its Class A shares on the Main Board of the Shenzhen Stock Exchange (Ticker: SZSE:001367), deploying the raised proceeds toward large-scale manufacturing capacity expansion, automated workshop upgrades, and the construction of an advanced research and development center. Furthermore, the company has recently broadened its international market reach through accelerated foreign regulatory drug master file (DMF) registrations, initiated commercial scale-up for newly developed API lines, and established long-term strategic supply partnerships with prominent domestic and multinational generic pharmaceutical enterprises.